Sarepta Therapeutics (SRPT) Change in Receivables (2010 - 2026)

Sarepta Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 105.95% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was -$264.6 million, a 194.29% decrease from a year earlier, with the FY2025 full-year figure at -$203.8 million, down 201.04% from the prior year.
• Change in Receivables fell to -$3.4 million in Q1 2026 per SRPT's latest filing, from $2.5 million in the prior quarter.
• Across five years, Change in Receivables topped out at $167.5 million in Q4 2024 and bottomed at -$132.1 million in Q2 2025.
• The 5-year median for Change in Receivables is $13.0 million (2023), against an average of $14.2 million.
• Across the five-year window, Change in Receivables soared 3598.81% in 2023 and slumped 602.2% in 2025, its largest moves.
• Year by year, Change in Receivables stood at $13.1 million in 2022, then surged by 521.02% to $81.5 million in 2023, then jumped by 105.55% to $167.5 million in 2024, then tumbled by 98.51% to $2.5 million in 2025, then tumbled by 236.97% to -$3.4 million in 2026.
• Per Business Quant, the three latest SRPT Change in Receivables figures stand at -$3.4 million (Q1 2026), $2.5 million (Q4 2025), and -$131.6 million (Q3 2025).